Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.38
-0.40 (-2.90%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.

It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.

The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc.
Mineralys Therapeutics logo
Country United States
Founded 2019
IPO Date Feb 10, 2023
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Jon Congleton

Contact Details

Address:
150 N. Radnor Chester Rd., Suite F200
Radnor, Pennsylvania 19087
United States
Phone 888 378 6240
Website mineralystx.com

Stock Details

Ticker Symbol MLYS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001933414
CUSIP Number 603170101
ISIN Number US6031701013
SIC Code 2834

Key Executives

Name Position
Jon Congleton Chief Executive Officer and Director
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. Founder and Executive Chairman
Adam Scott Levy Chief Financial Officer and Secretary
Dr. David M. Rodman M.D. Chief Medical Officer
Cindy Berejikian Executive Vice President of Operations
Sarah Foster Vice President of Human Resources
Dr. Robert McKean Ph.D. Senior Vice President of CMC
Danielle Bradbury Senior Vice President of Quality Assurance
Jeffrey N. Fellows Senior Vice President of Regulatory Affairs
Jessica Ibbitson Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 30, 2024 8-K Current Report
Oct 11, 2024 144 Filing
Oct 11, 2024 144 Filing
Sep 25, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 24, 2024 144 Filing
Jul 16, 2024 144 Filing
Jul 11, 2024 144 Filing
Jul 11, 2024 144 Filing